FDA OKs Boston Scientific’s New Taxus Stent

Law360, New York (October 13, 2008, 12:00 AM EDT) -- Boston Scientific Corp. has received federal clearance to bring its Taxus Liberte drug-eluting stent to market after waiting more than two years due to regulatory problems at the company’s facilities.

Boston Scientific said Friday that the U.S. Food and Drug Administration had approved its next-generation stent, and the company plans to start selling the device early next month in the United States.

The FDA sent an approvable letter to the Natick, Mass.-based company in March, stating that the firm had to meet certain requirements before its...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.